A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Official title

A Phase 1, First-time-in-human, Four-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)

Overview

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

Interventions

• Drug GSK4527363
  GSK4527363 will be administered to participants.
• Drug Placebo matching GSK4527363
  Placebo matching GSK4527363 will be administered to participants.
• Drug Belimumab
  Belimumab will be administered to participants.

Primary outcome measures

• Parts A and C: Number of Participants with Non-serious Adverse Events and Serious Adverse Events [Time frame: Up to Week 52]
• Parts B and D: Number of Participants with Non-serious Adverse Events and Serious Adverse Events [Time frame: Up to Week 68]
• Parts A and C: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) Findings [Time frame: Up to Week 52]
• Parts B and D: Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) Findings [Time frame: Up to Week 68]
• Parts A and C: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS) [Time frame: Up to Week 52]
• Parts B, and D: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS) [Time frame: Up to Week 68]

Secondary outcome measures (12)

• Parts A and C: Area Under the Concentration-time Curve to the Last Quantifiable Concentration (AUC[0-t]) of GSK4527363 [Time frame: Up to Week 52]
• Parts A and C: Area Under the Concentration-time Curve to Infinity (AUC[0-inf]) of GSK4527363 [Time frame: Up to Week 52]
• Parts A and C: Maximum Plasma Concentration (Cmax) of GSK4527363 [Time frame: Up to Week 52]
• Parts A and C: Apparent Terminal Phase Half-life (t1/2) of GSK4527363 [Time frame: Up to Week 52]
• Parts A and C: Number of Participants with Anti-drug Antibodies (ADAs) Against GSK4527363 [Time frame: Up to Week 52]
• Parts B and D: Number of Participants with Anti-drug Antibodies (ADAs) Against GSK4527363 [Time frame: Up to Week 68]
• Parts A, B and C: Titers of ADAs Against GSK4527363 [Time frame: Up to Week 52]
• Parts A and C: Percentage change from Baseline in cytokine levels [Time frame: Baseline (Day 1) and up to Week 52]
• Parts B and D: Percentage change from Baseline in cytokine levels [Time frame: Baseline (Day 1) and up to Week 68]
• Part B and D: Area Under the Concentration-time Curve of GSK4527363 [Time frame: Up to Week 12]
• Part B and D: Maximum Plasma Concentration of GSK4527363 [Time frame: Up to Week 12]
• Part B and D: Concentration at the end of the First Dosing Interval of GSK4527363 [Time frame: Up to Week 12]

Eligibility criteria

Inclusion criteria

For Part A and Part C (Healthy Participants):

• Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent form
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (vital signs and 12-lead ECG)
• Part C only: Be of Japanese (Cohort C1) or Chinese (Cohort C2) ancestry i. Born in Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2); and ii. Descendent of 2 ethnic Japanese (Cohort C1) or Chinese (Cohort C2) parents and 4 ethnic grandparents; and iii. Have lived outside Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2) for less than 10 years at the time of screening
• Body weight greater than or equals to (>=) 45 kilograms (kg)
• Body mass index (BMI) within the range 18-32 kilograms per square meter (kg/m\^2) (inclusive)
• Male or female of non-childbearing potential

For Part B (SLE participants):

• 18 to 65 years of age inclusive, at the time of signing the informed consent form
• Documented clinical diagnosis of SLE according to the (European alliance of associations of rheumatology \[EULAR\]/ American College of Rheumatology \[ACR\] SLE classification criteria)
• Body weight >= 45 kg
• BMI within the range 18-32 kg/m\^2 (inclusive)
• Male or female
• Capable of giving signed informed consent For Part D (CTD-ILD Participants)
• Participants must be 18 to 65 years of age, at the time of signing the informed consent form
• Documented clinical diagnosis of specific Connective Tissue Diseases in accordance with internationally recognised classification criteria
• Documented clinical diagnosis of interstitial lung disease (ILD) as determined by historical High-resolution computed tomography (HRCT)
• Participants must be on a stable dose of therapy to manage ILD and/or underlying connective tissue disease (CTD)
• Body weight >= 45 kg
• BMI within the range 18-32 kg/m\^2 (inclusive)
• Male or female
• Capable of giving signed informed consent

Exclusion criteria

For Part A and Part C (Healthy Participants):

• History or presence or cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders
• A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug
• Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks before dosing
• Symptomatic herpes zoster within 3 months prior to screening
• Have a history of malignancy, or a strong family history of malignancies related to immunosuppression
• Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions
• Abnormal blood pressure
• Evidence of active or latent Tuberculosis (TB)
• Alanine transaminase (ALT) >=1.1\* Upper limit of normal (ULN)
• Total bilirubin >1.0\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >=1.5\*ULN as long as direct bilirubin is less than or equal to (<=)1.5\*ULN
• Presence of Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
• Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
• Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
• Positive Human immunodeficiency virus (HIV) antibody test at screening
• Prior medical history of anaphylaxis
• QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec)
• Live vaccine(s) within 30 days before the dosing day or plans to receive such vaccines during the study

For Part B (SLE participants):

• Any acute, severe lupus related flare during the Screening Period that needs immediate treatment
• Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk
• Have an acute or chronic infection requiring management as follows:

i. Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria ii. A serious infection requiring treatment with antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed

• Evidence of active or latent TB
• Confirmed Progressive Multifocal Leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms
• ALT >2\*ULN
• Total bilirubin >1.5\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5\*ULN as long as direct bilirubin is >1.5\*ULN
• Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
• Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
• Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
• History or positive test at Screening for HIV
• QTcF >450 msec
• Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, Cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
• Live or live-attenuated vaccine(s) within 30 days prior to Screening

For Part D Participants:

• A diagnosis of: ILD other than CTD-ILD and/or SLE
• FVC <= 45% predicted at Screening Pulmonary arterial hypertension, as determined by the Investigator, prior to Day 1
• Major surgery (including joint surgery) within 3 months prior to Screening or planned during the duration of the study
• Previous or planned major organ transplant (e.g. heart, lung, kidney, liver) or bone marrow transplant (e.g. autologous stem cell transplant)
• Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to CTD-ILD (i.e., cardiovascular, metabolic, hematologic, GI, hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) which, in the opinion of the PI, could confound the results of the clinical study or put the participant at undue risk
• Have an acute or chronic infection including requiring management
• Evidence of active or latent TB
• Confirmed PML or unexplained new-onset or deteriorating neurologic signs and symptoms
• ALT >2\*ULN
• Total bilirubin >1.5\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5\*ULN as long as direct bilirubin is >1.5\*ULN
• Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
• Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
• Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
• History or positive test at Screening for HIV
• Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, CIN or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
• Live or live-attenuated vaccine(s) within 30 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Treatment

Study locations

United States · 6 centers

• GSK Investigational Site — Scottsdale
• GSK Investigational Site — Aurora
• GSK Investigational Site — Las Vegas
• GSK Investigational Site — Columbus
• GSK Investigational Site — Oklahoma City
• GSK Investigational Site — Dallas

Poland · 5 centers

• GSK Investigational Site — Bydgoszcz
• GSK Investigational Site — Krakow
• GSK Investigational Site — Poznan
• GSK Investigational Site — Warsaw
• GSK Investigational Site — Wroclaw

Spain · 5 centers

• GSK Investigational Site — Barcelona
• GSK Investigational Site — Bilbao
• GSK Investigational Site — Pamplona
• GSK Investigational Site — Sabadell Barcelona
• GSK Investigational Site — Valladolid

Argentina · 4 centers

• GSK Investigational Site — Buenos Aires
• GSK Investigational Site — Rosario
• GSK Investigational Site — San Juan Bautista
• GSK Investigational Site — San Miguel de Tucumán

Brazil · 4 centers

• GSK Investigational Site — Porto Alegre
• GSK Investigational Site — Juiz de Fora
• GSK Investigational Site — Porto Alegre
• GSK Investigational Site — Salvador

United Kingdom · 4 centers

• GSK Investigational Site — Cambridge
• GSK Investigational Site — Liverpool
• GSK Investigational Site — London
• GSK Investigational Site — Middlesex

Identifiers

NCT: NCT06576271 · 221458 · 2024-514186-18-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗